
ALPS Medical Breakthroughs ETF (SBIO) Price & Holdings
SBIONYSEARCASS&CEquity
As of Nov 20, 2026 close
- Assets (AUM)
- $211.51M
- Expense ratio
- 0.50%
- Dividend yield
- -
- Holdings
- 107
- 52-week range
- $45.65$70.85
- Volume (live)
- -
- Avg. volume (3M)
- 27.14K
SBIO ETF Price Chart
Loading chart...
SBIO Key Statistics & Financial Metrics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $50.87 - $52.87 |
|---|---|
| 52-Week High | $70.85 |
| 52-Week Low | $45.65 |
| Open | $52.29 |
| Volume (last close) | 62.22K |
| Average Volume (3M) | 27.14K |
| 1 Day Change | −0.71% |
|---|---|
| 1 Month Change | −3.74% |
| 6 Month Change | −2.36% |
| YTD Change | +4.72% |
| 1 Year Change | +11.64% |
| 5 Year Change | +16.81% |
| 10 Year Change | +103.68% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Last Dividend Ex-Date | Dec 19, 2024 |
| Dividend Growth YoY | −100.00% |
| Years Dividend Growth | 1 |
| Assets (AUM) | $211.51M |
|---|---|
| Expense Ratio | 0.50% |
| Total Holdings | 107 |
| Inception Date | Dec 30, 2014 |
| 50-Day MA | $56.30 |
|---|---|
| 200-Day MA | $57.24 |
| RSI | 40.57 |
| Stochastic %K | 4.68 |
| Stochastic %D | 6.33 |
Source: Exchange price data and fund disclosures. Data as of Nov 20, 2026. Data sources and methodology
SBIO at a Glance
ALPS Medical Breakthroughs ETF (SBIO) is an equity ETF from SS&C, launched in December 2014. It manages $211.51M in assets and charges a 0.50% expense ratio, about $50 a year per $10,000 invested.
Based on holdings data updated Oct 4, 2026, it holds 107 positions. The largest are CG Oncology, Inc. (CGON, 3.88%), Oruka Therapeutics, Inc. (ORKA, 3.64%) and Travere Therapeutics, Inc. (TVTX, 3.49%). The top 10 holdings make up 32.5% of the fund. By sector it leans toward Healthcare (100.0%). 91.5% of assets are in the United States.
It does not currently pay distributions. As of the Nov 20, 2026 close, the share price is up 11.6% over one year, up 16.8% over five years and up 103.7% over ten years (price change, excluding distributions).
Frequently Asked Questions About ALPS Medical Breakthroughs ETF
What is the current price of SBIO?
The latest SBIO price is $50.95 (Nov 20, 2026 close). The 52-week range is $45.65–$70.85. The share price is up 11.6% over the past year (price change, excluding distributions).
What is the expense ratio for SBIO?
SBIO's annual expense ratio is 0.50%, about $50 a year for every $10,000 invested.
Does SBIO pay dividends?
ALPS Medical Breakthroughs ETF has paid no distributions in the trailing 12 months to the Nov 20, 2026 close. Its most recent recorded distribution was $1.17 per share, with an ex-dividend date of December 19, 2024.
What are the top holdings of SBIO?
In holdings data last updated Oct 4, 2026, SBIO's largest holdings are CG Oncology, Inc. (3.9%), Oruka Therapeutics, Inc. (3.6%), Travere Therapeutics, Inc. (3.5%) (combined weight: 11.0%). The fund holds 107 total positions. View the complete portfolio breakdown in the Holdings section.
How concentrated is SBIO's portfolio?
In holdings data updated Oct 4, 2026, the top 10 holdings make up 32.5% of SBIO's assets across 107 positions. Its largest sector weight is Healthcare at 100.0%.
How large is SBIO and when did it launch?
SBIO manages $211.51M in assets. SS&C launched the fund on December 30, 2014, about 11 years before the Nov 20, 2026 close.